title: [CD30-positive anaplastic large cell T-cell lymphoma developing during immunosuppressive therapy of pityriasis rubra pilaris with ustekinumab].
abstract: The development of malignancies during therapy with biologics has been discussed controversially. A patient with extensive pityriasis rubra pilaris failed to respond to standard therapeutic approaches. While receiving immunomodulatory therapy, lastly with ustekinumab, the patient developed a CD30(+) anaplastic large cell lymphoma.
authors: Klinik für Dermatologie, Venerologie und Allergologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin. daniel.humme@charite.de
authors: D
authors: D
authors: Humme
authors: M
authors: M
authors: Beyer
authors: H-J
authors: HJ
authors: Röwert-Huber
authors: W
authors: W
authors: Sterry
authors: S
authors: S
authors: Philipp
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017728:Lymphoma, Large-Cell, Anaplastic / Q000139:chemically induced* / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D010916:Pityriasis Rubra Pilaris / Q000188:drug therapy*; D000069549:Ustekinumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069549:Ustekinumab